Replies to post #12984 on Momenta Pharmaceuticals, Inc. (MNTA)

[semi_infinite]

RE "Maxim Group downgraded Momenta Pharmaceuticals (NASDAQ: MNTA) from Hold to Sell with a price target of $7.00 (from $17.00) after the Supreme Court has sent the Copaxone fight over the validity of Teva's (NASDAQ: TEVA) patents back to the Court of Appeals Federal Circuit (CAFC) where the case will be heard over the next year. "

That's a big delta in price target because of a shift of 8 months in timeline. I wonder what changed in his dcf model that would cause such a >50% drop in DCF. Any thoughts?